Top 8% Drugmaker Hikes Guidance On The Back Of Its Mixed Third Quarter

Viatris reported flat Q3 revenue of $3.75B and a net loss of $0.28 per share. Growth in Greater China and North America was offset by supply constraints and competition. Gross margin improved to 38% due to higher-margin product sales, while manufacturing disruptions cost $100M in revenue.

Viatris VTRS reported Q3 2026 revenue of $3.7B, missing estimates by $40M, with a 3% YoY decline in generics sales due to supply constraints. Brands segment grew 1% YoY. Adjusted EPS rose 6% to $0.71, beating forecasts, with a 200 bps gross margin improvement.

Viatris (VTRS) reported Q3 2026 revenue of $3.7B, missing estimates, while earnings exceeded expectations. Generics sales declined for the first time this year. The company attributed the revenue miss to lower sales in its generics segment.

Viatris Inc (VTRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Viatris Reports Third-Quarter 2026 Financial Results • Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion • Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan • Returns Approximat

Viatris (VTRS) reported Q3 EPS of $0.71, beating estimates by $0.07, but revenue of $3.75B missed expectations. The company forecasted FY 2026 EPS of $2.56-$2.63 and revenue of $14.70B-$14.90B, slightly below consensus. The stock is up 16.98% in the last 3 months and 90.11% in the last 12 months.

Viatris Inc (VTRS) reported a Q3 loss of $325.3 million, or 28 cents per share. Adjusted earnings were 71 cents per share, beating estimates of 64 cents. Revenue was $3.75 billion, missing forecasts of $3.78 billion. The results exceeded earnings expectations but fell short on revenue.